What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.


Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D.
Stanford University

Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D.
Stanford University

Julie A. Johnson, Pharm.D.
University of Florida

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larissa Cavallari, Pharm.D.
University of Florida

Stuart Scott, Ph.D.
Icahn School of Medicine at Mount Sinai

Scientific Advisory Board

Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories

Robert Nussbaum, M.D.
University of California, San Francisco

Heidi Rehm, Ph.D.
Partners Healthcare

Marc S. Williams, M.D.

Sandy Aronson
Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D.
Northwestern University

  • Call for clarification on antidepressant pharmacogenomics November 5, 2019
    A new Perspective in Clinical Pharmacology and Therapeutics outlines the need for improved communication from pharmacogenomic testing companies and regulators on the role of pharmacogenomics in antidepressant therapy.Beginning antidepressant treatment can be an arduous experience for patients. Some patients fail to respond to first-line antidepressants, leading to an iterative process of trying different medications until depressive […]
  • CYP2D6 Genotype to Phenotype Standardization Project results published November 1, 2019
    The consensus of the CYP2D6 Genotype to Phenotype Standardization Project is just published in Clinical and Translational Science. To address inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG)) and between clinical genetic testing laboratories, CPIC recently conducted a modified-Delphi project to obtain consensus among a panel of […]
  • Public comment period for CPIC allele function assignment SOP October 10, 2019
    CPIC is inviting public comments on their draft SOP for assigning function to pharmacogenomic alleles.CPIC has been assigning “function” to pharmacogenomic alleles since its inception. This has already led to a Delphi process and consensus publication on standardizing terms used for allele function and pharmacogenetic phenotypes for some genes. The unique contribution of CPIC is to […]
  • ACLA writes to the FDA about PGx testing September 20, 2019
    The American Clinical Laboratory Association (ACLA) has written a letter to the US Food and Drug Administration (FDA) regarding the FDA’s recent communications about pharmacogenomic (PGx) testing. The letter details the ACLA’s concerns that the FDA’s actions will have a significant impact on both patients and the field of PGx. The ACLA state their support […]
  • Michelle Whirl-Carrillo -- Director of the PharmGKB! September 10, 2019
    We are happy to announce that Dr. Michelle Whirl-Carrillo has agreed to take on the position of Director of PharmGKB. Michelle has worked with the PharmGKB for over 15 years (not including a 1.5 year “sabbatical” at 23andme). She has served as lead curator, Assistant Director, and (since 2014) Associate Director. The PharmGKB grant has […]